1. Home
  2. TBPH vs LINC Comparison

TBPH vs LINC Comparison

Compare TBPH & LINC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • LINC
  • Stock Information
  • Founded
  • TBPH 2013
  • LINC 1946
  • Country
  • TBPH United States
  • LINC United States
  • Employees
  • TBPH N/A
  • LINC N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • LINC Other Consumer Services
  • Sector
  • TBPH Health Care
  • LINC Real Estate
  • Exchange
  • TBPH Nasdaq
  • LINC Nasdaq
  • Market Cap
  • TBPH 485.8M
  • LINC 507.8M
  • IPO Year
  • TBPH N/A
  • LINC 2005
  • Fundamental
  • Price
  • TBPH $9.59
  • LINC $15.45
  • Analyst Decision
  • TBPH Buy
  • LINC Strong Buy
  • Analyst Count
  • TBPH 4
  • LINC 4
  • Target Price
  • TBPH $13.75
  • LINC $18.00
  • AVG Volume (30 Days)
  • TBPH 217.1K
  • LINC 130.6K
  • Earning Date
  • TBPH 11-12-2024
  • LINC 11-11-2024
  • Dividend Yield
  • TBPH N/A
  • LINC N/A
  • EPS Growth
  • TBPH N/A
  • LINC N/A
  • EPS
  • TBPH N/A
  • LINC 0.32
  • Revenue
  • TBPH $63,192,000.00
  • LINC $423,213,000.00
  • Revenue This Year
  • TBPH $11.41
  • LINC $16.59
  • Revenue Next Year
  • TBPH $37.36
  • LINC $10.43
  • P/E Ratio
  • TBPH N/A
  • LINC $48.30
  • Revenue Growth
  • TBPH 15.93
  • LINC 15.21
  • 52 Week Low
  • TBPH $7.44
  • LINC $8.91
  • 52 Week High
  • TBPH $11.71
  • LINC $18.74
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 50.13
  • LINC 47.07
  • Support Level
  • TBPH $9.62
  • LINC $14.95
  • Resistance Level
  • TBPH $10.08
  • LINC $16.45
  • Average True Range (ATR)
  • TBPH 0.31
  • LINC 0.60
  • MACD
  • TBPH -0.06
  • LINC -0.21
  • Stochastic Oscillator
  • TBPH 25.00
  • LINC 24.27

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About LINC Lincoln Educational Services Corporation

Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services and business and information technology. Its reportable segments include; Campus Operations, and Transitional. Majority of the revenue is generated from Campus Operations segment which includes all campuses that are continuing in operation and contribute to the Company's core operations and performance.

Share on Social Networks: